Biochips market forecast points to rapid growth through 2033

By AI, Created 10:55 AM UTC, May 22, 2026, /AGP/ – Coherent Market Insights says the global biochips market is set to nearly double between 2026 and 2033, driven by demand across diagnostics, drug discovery and microfluidics. The report also maps the competitive landscape, regional outlook and key players including Thermo Fisher Scientific, Agilent Technologies and bioMérieux.

Why it matters: - The biochips market is projected to expand from USD 21,996.6 million in 2026 to USD 48,138.1 million by 2033. - The forecast points to growing demand in diagnostics, drug development and delivery, and other life-sciences uses. - The report is aimed at businesses, investors and industry participants tracking where the next wave of spending may land.

What happened: - Coherent Market Insights published a new report, “Biochips Market Forecast 2026-2033,” on May 22, 2026. - The study covers global and country-level forecasts, competitive conditions, supply chain shifts and market dynamics. - The report includes a sample request link: Get the sample copy.

The details: - The report breaks the market down by type, technology, application and end user. - By type, the study covers DNA microarray, microfluidic chip, protein microarray and others. - By technology, the report focuses on microarrays and microfluidics. - By application, the report covers diagnosis, drug discovery and development, drug delivery and others. - By end user, the report includes biotechnological and pharmaceutical companies, hospitals, diagnostic centers and others. - The report highlights historical data, future forecasts, revenue-share analysis, regional insights and industry trends. - The study evaluates competitive developments such as expansions, product launches, acquisitions and collaborations. - The report includes SWOT analysis and Porter’s Five Forces. - The top companies listed include Thermo Fisher Scientific, Agilent Technologies, Illumina, Bio-Rad Laboratories, QIAGEN, F. Hoffmann-La Roche, Abbott Laboratories, Standard BioTools, bioMérieux and Revvity.

Between the lines: - The report frames biochips as a market shaped by both technology shifts and commercial competition. - Microfluidics and microarrays remain the core technologies to watch. - The inclusion of regional demand patterns suggests the market may not grow evenly across geographies. - The emphasis on company benchmarking signals that consolidation, partnerships and product launches could remain important competitive tools.

What’s next: - The report says the updated version and online dashboard are designed to help users track market changes and identify opportunities. - The company says the research can support strategic decision-making, investment planning and competitive mapping. - The full report is available through the purchase link: Buy the report.

The bottom line: - Biochips are moving from a niche research category toward a larger commercial market, with diagnostics and microfluidics driving much of the expected growth.